PT - JOURNAL ARTICLE AU - Vadim Testov AU - Sergey Sterlikov AU - Irina Vasilyeva AU - Vladislav Erokhin AU - Teresa Kasayeva TI - Impact of social support programme on MDR-TB patients' treatment outcomes DP - 2014 Sep 01 TA - European Respiratory Journal PG - P2682 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P2682.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P2682.full SO - Eur Respir J2014 Sep 01; 44 AB - Objective To define impact of social support programme on MDR-TB patients' treatment outcomesIntroduction 5.206 MDR-TB patients were enrolled for treatment in civilian sector of 26 Russian regions in 2008 -2010 within GF Round 4 project. The GF Round 4 project implemented social support programme as tool to increase TB patients' adherence. Patients on outpatient treatment received weekly food and hygienic sets. The cost of sets comprised 20 $US per month/per capita. 3.738 MDR-TB patients (including 1.328 new cases, 602 relapses and 1.808 - from other groups of retreatments) were covered by the social programme and 1.468 patients (including 455 new cases, 228 relapses and 785 from other groups of retreatmnets) didn't receive social support due to termination of GF Round 4 project.Results. Treatment success rate comprised 50.7% for covered by social support programme MDR-TB patients and 47.2% for patients who didn't received social support (p=0.03). There were no different in treatment success and default rates between new MDR-TB cases and relapses who received and who didn't receive social support (p>0,1). Other retreatments (including patients from registration groups: treatment after default, treatment after failure of category I and II and other) showed reliable different in default rate - 21.3% for patients who received social support component and 28.4% for patients treated without social support component (p<0,01).Conclusion. Presented model of social support programme demonstrated improvement of patients' adherence only for retreatments with treatment problems in the past. Impact of this model on treatment outcomes of new MDR-TB cases and relapses was not found.